Fulcrum Therapeutics Announces Recent Business Highlights an

― Completed enrollment in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD); expect to report topline data in...

Related Keywords

United States , Canada , Cambridge , Cambridgeshire , United Kingdom , Chris Calabrese , Alexc Sapir , Linkedin , Exchange Commission , Drug Administration , Embryonic Ectoderm Development , Lifesci Advisors , Fulcrum Therapeutics Inc , Investigational New Drug , Investor Relations , Orphan Drug Designation , Fast Track , Private Securities Litigation Reform Act , Sci Advisors ,